VONHF yields 5.37% · JNJ yields 2.13%● Live data
📍 VONHF pulled ahead of the other in Year 1
Combined, VONHF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VONHF + JNJ for your $10,000?
Vontobel Holding AG provides various financial services to private and institutional clients. The company operates through Asset Management, Platforms & Services, Wealth Management, and Digital Investing segments. The Wealth Management segment offers managed solutions, advisory services, and investment products; and financial planning and consulting, pension planning, succession planning, and estate planning solutions, as well as real estate financing and Lombard loans. The Asset Management segment provides equities, fixed income, multi asset, and fund solutions. The Platforms & Services segment offers various platforms, such as EAMNet, an integrated and centralized product and services platform that provides trading, and reports to research services; deritrade, a multi-issuer platform that offers designing and issuing bespoke structured products; cosmofunding, a money and capital market platform that provides securitization of classic loan and private placement; investerest, a social investing market place; derifactory, a white-labeling platform for structured products; and electronic trading solutions for professionals, as well as structured investments, funds, investment strategy/research, EAM, ESG, and ESG insights and news solutions. The Digital Investing segment provides Vontobel Volt, a digital wealth management platform; investerest, a social investing market place that combines and standardizes the entire strategy and investment spectrum; and structured and leverage investment services. Vontobel Holding AG was founded in 1924 and is headquartered in Zurich, Switzerland.
Full VONHF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.